Skip to main content
. Author manuscript; available in PMC: 2016 Sep 14.
Published in final edited form as: Oncogene. 2016 Mar 14;35(29):3829–3838. doi: 10.1038/onc.2015.453

Figure 4. Ablation of TAK1 augments SREBP activity.

Figure 4

(A, B) HEK293 cells were treated with three independent siRNAs targeted against TAK1, and SRE-luciferase and control EF1α-renilla luciferase vectors were subsequently transfected at one-day post siRNA introduction. Cells were left untreated or treated with methyl-β-cyclodextrin 6 h before the cell harvesting. Proteins were analyzed by immunoblotting (A). Luciferase activity is normalized to renilla luciferase activity (B). Means ±SD; n = 3; ***, p < 0.001 (one-way ANOVA). (C) A vector expressing small hairpin RNA targeted against TAK1 was transfected into HepG2 cells. Cells were subsequently transfected with the expression vectors for mature SREBPs and the same reporters used in (A, B). Proteins were analyzed by immunoblotting to determine the protein level of TAK1 (right panes). The level of TAK1 was not altered by the 2nd transfections. Luciferase activity is normalized to renilla luciferase activity. Means ±SD; n = 3; **, p <0 .01; ***, p < 0.001 (two-tailed unpaired Student’s t test).